Dr. Noah Federman’s main scientific interest has been in the field of nanotechnology: developing nanoparticles to specifically target sarcomas and deliver cytotoxic chemotherapy. This novel research may lead to new breakthroughs in targeted therapies for cancer. As a member and institutional principle investigator for the Sarcoma Alliance Research Through Collaboration (SARC), Federman leads an experienced pediatric sarcoma clinical research team with an emphasis towards studying promising new agents in children with very aggressive and often fatal metastatic and refractory bone and soft tissue cancers.
Selected Cancer-Related Publications:
Federman N, Bernthal N, Eilber FC, Tap WD. The multidisciplinary management of osteosarcoma. Curr Treat Options Oncol. 2009 Apr;10(1-2):82-93. Epub 2009 Feb 24.
Benz MR, Tchekmedyian N, Eilber FC, Federman N, Czernin J, Tap WD. Utilization of positron emission tomography in the management of patients with sarcoma. Curr Opin Oncol. 2009 Jul;21(4):345-51.
Federman N, Sakamoto K. Nonrhabdomyosarcoma soft tissue sarcomas. Emedicine. Dec 2008.
Tap WD, Federman N, Eilber FC. Targeted therapies for soft-tissue sarcomas. Expert Rev Anticancer Ther. 2007 May;7(5):725-33.
Federman N, Feig SA. PET/CT in evaluating pediatric malignancies: a clinician's perspective. J Nucl Med. 2007 Dec;48(12):1920-2.